Publications
40
Citations
808
Est. group size
~1
Recurring co-author estimate
Active years
37
Publishing since 1989
This publication record appears to combine at least two distinct areas: preclinical cancer research on a drug candidate (a PLK1 inhibitor tested against diffuse large B-cell lymphoma) and separate work on culture-of-inclusion and diversity topics in professional/organizational settings. The bibliographic data does not clearly indicate a single, unified research program, so prospective students should verify directly which line of work this person currently leads.
Publication output was minimal or absent for most of the decade but spiked sharply in 2023 with a large cluster of supplementary materials from a single lymphoma drug study, followed by a smaller, steadier stream of inclusion-related items in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Growing Intercultural Global Energy Leaders
2025
- The Value of Assessing, Reporting, and Discussing Culture of Inclusion (Experience)
2024
- Benefits of the Culture of Inclusion Survey
2024
- Supplementary Table 2 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Supplementary Figure 3 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Supplementary Figure Legend from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Supplementary Figure 2 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Supplementary Figure 4 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Supplementary Table 1 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Supplementary Figure 1 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Supplementary Figure Legend from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Supplementary Figure 4 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Supplementary Figure 3 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Supplementary Figure 1 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Supplementary Figure 2 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023
- Journal of the American Psychiatric Nurses Association×1
- Public Health Nursing×1
- Journal of Psychosocial Nursing and Mental Health Services×1
- 2021 ASEE Virtual Annual Conference Content Access Proceedings×1
- Lapo Alinari
Medicine · The Ohio State University
- Beth Christian
Medicine · The Ohio State University
- Hui Yu
Medicine · The Ohio State University
- David A. Bond
Medicine · The Ohio State University
- Jayalakshmi Balakrishna
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile